EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
about
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complexRel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptorsSKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC functionA role for SKIP in EBNA2 activation of CBF1-repressed promotersNuclear localization of CBF1 is regulated by interactions with the SMRT corepressor complexA histone deacetylase corepressor complex regulates the Notch signal transduction pathwayTruncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiationEBNA2 and activated Notch induce expression of BATFInterferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuitProtein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins.Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptovirusesThe latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promotersDNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirusProtein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virusA somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent.Evolutionary aspects of oncogenic herpesvirusesEpstein-Barr virus EBNA2 blocks Nur77- mediated apoptosisThe importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.Epstein-barr virus, the immune system, and associated diseasesEpstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4.The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activityThe EBNA-2 N-Terminal Transactivation Domain Folds into a Dimeric Structure Required for Target Gene Activation.Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation.Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B siteContribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJkAn EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP genec-Rel plays a key role in deficient activation of B cells from a non-X-linked hyper-IgM patient.Molecular genetic analysis of Epstein-Barr virus Cp promoter functionTranscription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growthAn auto-regulatory loop for EBV LMP2A involves activation of Notch.Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial.Mitosis-specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function.Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth.MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.Four EBNA2 domains are important for EBNALP coactivation
P2860
Q22008610-404B2EFD-51CD-4C0F-9DE4-A41E105D74F6Q22010043-DFAFA14F-6616-45C8-BB46-FB05DF59B62EQ22253329-BC17E931-2BA5-4E77-A42D-917B5E9E7CE9Q24524363-BC257739-60DD-4080-AB6B-03D38A4A3A2BQ24550850-CAB3ABB0-B3A6-4BDC-A2E5-44CC8991B8F1Q24598533-8559C512-2A5F-48D7-A2E8-3CD6C718EB96Q24650743-F4574168-4366-4FDC-A27F-42756A8E3658Q24678677-1A8E19A4-06B8-444C-B277-8624A8A36BD1Q24679432-DD35A821-0195-49D2-819F-2000943CD243Q24683031-392864C7-7236-4690-AF39-0325DAA8A713Q28114910-1E450FCE-3A80-4A8B-B958-652D49890879Q33639938-82008133-87D3-4862-BE2A-3FBDF9EFAD8CQ33754919-689F6AD6-3386-4906-A754-EE4D67AF8B92Q33795078-5F578EA8-A909-4463-8A0E-39A9216F3BF8Q33845947-2B117C41-F3DD-4954-958D-82D425402E71Q33853499-863B28A4-D142-418D-9504-3176BBE746C4Q33865166-5C273002-1E7C-45BC-A0AD-AE716AACC08BQ33884014-00A58AE9-42E6-4B90-A51E-6DC48C5E8842Q34089478-D4EE093D-DA20-400A-A4B7-62EAE2A780B7Q34154616-6E44FDFE-5999-4ECD-8968-5D6F26BDBF4EQ34549462-C39BC125-1A5F-498A-92F1-79D02215B8D0Q35024009-9E0B7EC0-928C-4BB0-98D3-8921CFA5F97DQ35029255-ED8334DC-07C1-46B8-9C1E-6756D9F148D9Q35539925-912CC3FE-9426-42F9-8DDC-636B571CFA18Q35603820-7D010F61-8CDD-4A98-A490-39D3A6D0033EQ35664999-C9FB10C9-28B4-461E-BA8C-52954BA90EE1Q35732134-2E7477F9-0833-4C87-8270-F2EB67E36699Q35831774-FA74E18A-F72B-408A-901F-E71DB6E1D897Q35835726-BE5CA11F-ADEB-40FF-9F8B-2953E8066E79Q35838226-65B9555B-148D-4533-B8B8-B6C8598315C2Q35848908-13B8AD09-ABDE-4F2E-BC97-FA1798D2ABF1Q35856784-88DBB7A2-8454-4AB4-AD47-85EE1DED2C9AQ35861192-5E10A7E3-8278-47B4-8739-7DE0C75A3914Q36525145-8D2A9164-187C-4B97-AF24-C3DD6496184DQ36528115-D3BEE96D-8648-4984-BFDC-3C40F8D07D90Q36555784-9D7C52D0-70F7-4B9E-943F-1DAF4A31139AQ37009375-E6FCC040-6F69-40A0-B9F9-29D7CB2381B2Q37132783-7F185BBA-B554-43A2-9162-28BDAEB8DA35Q37217649-34C6E749-38D9-4CDC-A761-442D68E17BB6Q37567915-C2960B55-9228-47C1-AF47-DC61619A4683
P2860
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
EBNA-2 upregulation of Epstein ...... targeting intermediate, CBF1.
@en
type
label
EBNA-2 upregulation of Epstein ...... targeting intermediate, CBF1.
@en
prefLabel
EBNA-2 upregulation of Epstein ...... targeting intermediate, CBF1.
@en
P2093
P2860
P1433
P1476
EBNA-2 upregulation of Epstein ...... n targeting intermediate, CBF1
@en
P2093
P2860
P304
P407
P577
1994-09-01T00:00:00Z